ACL Injury

Shares of Mesoblast limited (ADR) (NASDAQ: MESO) were trading lower by more than 1 percent on Friday despite announcing earlier in the day positive Phase 2a trial data. Mesoblast is engaged in the development of adult stem cell technology platforms. The company announced that results from a...